Wdr12 polymorphisms associated with myocardial infarction, methods of detection and uses thereof
CA 2886504 C · Owner: Celera Corporation · Inventors: Devlin, James J.; Cargill, Michele; Iakoubova, Olga
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention is based on the discovery of genetic polymorphisms that are , associated with myocardial infarction. In particular the present invention , relates to a , method for determining a human's risk for myocardial infarction (MI) comprising testing , nucleic acid from said human for the presence or absence of a polymorphisrn in gene WD , repeat domain 12 (WDR12) at position corresponding to position 101 of SEQ ID NO:77 , or its complement.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 22, 2003 and granted January 8, 2019. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 22, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 22, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.